Figure 7

In vivo antitumor activity of T1E28z-transduced T cells against a slowly progressive head and neck tumor xenograft. (A) HN3 tumor cells were engineered to express firefly luciferase (HN3-LUC) and were propagated as IP xenografts. In this representative example, a large established tumor was imaged by PET using ¹⁸F-fluorodeoxyglucose (tumor center indicated by crosshairs) or BLI, following administration of luciferin. (B) Five mice were inoculated intraperitoneally with 5 × 10⁶ HN3-LUC tumor cells and analyzed by BLI at the indicated intervals. (C) HN3-LUC tumors were recovered from mice described in (B) and analyzed by FACS for expression of ErbB1 and ErbB2. Comparison was made with HN3-LUC cells cultured in vitro. Filled histograms show staining with isotype control alone. (D) Twenty-five SCID Beige mice were inoculated with 5 × 10⁶ HN3-LUC tumor cells, administered by the IP route. Tumor take was confirmed on d 8 by BLI. On d 13, mice were treated with T cells transduced with T1E28z (n = 7), T1NA (n = 6), T4 (combination of 4αβ and T1E28z; n = 6) or PBS (n = 6). Analysis of T cells before infusion is shown in Supplementary Figure 4. Mean bioluminescence for each group is shown over the course of the study. ***P < 0.001 (T1E28z versus PBS and T4 versus PBS); *P < 0.05 (T1E28z versus PBS and T4 versus PBS); ‡P < 0.001 (T4 versus PBS) and P < 0.01 (T1E28z versus PBS); ‡‡P < 0.001 (T4 versus T1NA) and P < 0.01 (T1E28z versus T1NA). (E) Serial imaging of the same mouse (median representative of each group) is shown at selected time points over the course of the study. (F) Bioluminescence data at all time points for each mouse are shown.